TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10919304
Drug: bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 15 mg + morphine 5 mg + intraarticular methylprednisolone 40 mg
Study: 9010697
Drug: Candoxatril 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 25 mg b.i.d.
Study: 9010697
Drug: Candoxatril 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 100 mg b.i.d.
Study: 9010697
Drug: Candoxatril 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 400 mg b.i.d.
Study: 1490141
Drug: Methylprednisolone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (100 mg/day initially)
Study: 28211285
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) combined with femoral nerve block (FNB) - 150 mL mixture of ropivacaine 2.0 mg/mL + ketorolac 30 mg + adrenaline 10 μg/mL
Study: 12972476
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate 2 mg
Study: 12972476
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate 1 mg
Study: 12972476
Drug: IV ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronate 0.5 mg
Study: 12972476
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of ibandronate
Study: 10712859
Drug: Clove oil
Normalized name: Clove Oil
DrugBank: Clove oil (DB11338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clove oil carrier solution
Study: 8665577
Drug: MK-462 20
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-462 20 mg
Study: 8665577
Drug: MK-462 40
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-462 40 mg
Study: 1388093
Drug: Provera 500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provera 500-mg tablet
Study: 1388093
Drug: Farlutal 500-mg
Normalized name: medroxyprogesterone acetate Injectable Suspension [Farlutal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farlutal 500-mg tablet
Study: 1388093
Drug: Provera 500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provera 500-mg granule packet
Study: 3916620
Drug: Computer-assisted meal-related
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted meal-related insulin therapy (CAMIT = 3-4 injections daily)
Study: 3916620
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT = 2-3 injections daily)
Study: 26549402
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg/d)
Study: 27043753
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (control group with exact copy of text from MCG)
Study: 2853441
Drug: 1% nedocromil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% nedocromil sodium nasal spray given four times daily for four weeks
Study: 2853441
Drug: 1% nedocromil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% nedocromil sodium nasal spray
Study: 27571889
Drug: Interactive web‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive web‐based sleep intervention based on cognitive behavioral therapy principles
Study: 14761905
Drug: General medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: General medicine trials
Study: 10188788
Drug: CI‐979/RU35926 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI‐979/RU35926 (doses of 0.002-1.0 mg, with cholinergic symptoms observed at 2-4 mg)
Study: 16956475
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of ketorolac administered intravenously 30 minutes before surgery
Study: 16956475
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously 30 minutes before surgery
Study: 9028694
Drug: Levosulpiride (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (25 mg t.i.d. orally for 6 months)
Study: 3303693
Drug: Pharmaxolon treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaxolon treatment for 20 days
Study: 26952346
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg)
Study: 18506387
Drug: Apomorphine (Apo)
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine (Apo) 7 microg/kg sc, administered in seven injections at 2-hour intervals
Study: 18506387
Drug: Placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiological saline), administered in seven injections at 2-hour intervals
Study: 14659379
Drug: Qi-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi-therapy
Study: 10774682
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral artemether
Study: 10774682
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg intramuscular artemether
Study: 10774682
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg suppository artemether
Study: 10774682
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral artesunate (Guillin formulation)
Study: 10774682
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral artesunate (Arenco formulation)
Study: 10774682
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral dihydroartemisinin
Study: 6603249
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate 500 mg every six hours for seven days
Study: 6603249
Drug: Erythromycin or
Normalized name: erythromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin or placebo preparation for a further week
Study: 30866943
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm of a double-blind randomized vaccine trial
Study: 25577869
Drug: Astaxanthin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (25 mg x kg(‐1) x d(‐1) x bw(‐1)) from day 5 to 20 of pregnancy
Study: 25577869
Drug: L-NAME (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (125 mg x kg(‐1) x d(‐1) x bw(‐1)) from days 10-20 of pregnancy
Study: 21295843
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg PGF given 48 h prior to embryo collection (Treated cycle)
Study: 21295843
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg PGF given at embryo collection (Control cycle)
Study: 15535485
Drug: Abdominal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal lavage with normal saline solution (3000 to 6000 ml)
Study: 11499536
Drug: PUVA (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA (oral 8‐MOP plus UVA)
Study: 11499536
Drug: PUVB (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVB (oral 8‐MOP plus UVB)
Study: 8860097
Drug: Diuretics (95%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (95% thiazides and related agents) with high dietary sugar intake
Study: 8860097
Drug: Diuretics (95%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (95% thiazides and related agents) with low dietary sugar intake
Study: 1512524
Drug: Indobufen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (400 mg/day)
Study: 1512524
Drug: Dipyridamole (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (225 mg/day) plus Acetylsalicylic Acid (1 g/day)
Study: 30803503
Drug: Freeze-dried bilberry
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried bilberry (40 g/d) and standard medical therapy
Study: 30803503
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard medical therapy alone
Study: 22338863
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (AA group, n = 22)
Study: 22338863
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid and glucose infusion (AAGlu group, n = 18)
Study: 20207123
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 130 mg DHA per day
Study: 20207123
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 0 mg DHA per day (control)
Study: 17221933
Drug: Secnidazole 500
Normalized name: secnidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole 500 mg oral dosage
Study: 17221933
Drug: Reference secnidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference secnidazole tablets
Study: 29300100
Drug: UC +
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC + CALM ARC (7-session, group-based, computer-assisted but therapist-directed treatment)
Study: 25917860
Drug: Heated lidocaine/tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated lidocaine/tetracaine patch
Study: 11128360
Drug: Combined ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ramipril treatment
Study: 11128360
Drug: Ramipril (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (both doses)
Study: 6374533
Drug: Single 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 150 mg intramuscular dose of netilmicin
Study: 6374533
Drug: Five-day course
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day course of oral co-trimoxazole
Study: 24318410
Drug: Continuous absorbable
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous absorbable intradermal sutures
Study: 16355647
Drug: Supervised tooth-brushing
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised tooth-brushing with 1.23% APF gel (1 minute once a week)
Study: 12386505
Drug: Pulmonary artery
Normalized name: Pulmonary artery blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary artery catheter (PAC) led therapy
Study: 201440
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg fluoride as NaF in a watery solution
Study: 201440
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg fluoride in tablet form (D‐Fluoretten 1000)
Study: 28032641
Drug: Early tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early tumor shrinkage (ETS) observed in first-line treatment
Study: 28032641
Drug: Early tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early tumor shrinkage (ETS) in second-line therapy
Study: 28032641
Drug: Minor early
Normalized name: Vinca minor extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minor early tumor shrinkage (mETS) in second-line therapy
Study: 28032641
Drug: Minor progression
Normalized name: Vinca minor extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minor progression (mPD) in second-line therapy
Study: 28032641
Drug: Progression (PD)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progression (PD) in second-line therapy
Study: 23660094
Drug: Inosine within
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine within 6 hours (600 mg twice a day for 10-14 days)
Study: 23660094
Drug: Inosine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine after 6 hours (600 mg twice a day for 10-14 days)
Study: 23660094
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy group (routine treatments)
Study: 9667227
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MEL) 12 mg orally
Study: 2657467
Drug: Pyridostigmine 60
Normalized name: pyRIDostigmine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 60 mg orally
Study: 9667227
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MEL and pyridostigmine
Study: 9667227
Drug: Naloxone (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.2 mg bolus followed by i.v. infusion of 1.6 mg/h for 3 hours)
Study: 8134442
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy at 2.5 atmospheres for 90 minutes, 5 days per week for 30 treatments
Study: 8134442
Drug: Air therapy
Normalized name: Amlactin Foot Repair Therapy 15% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air therapy at 2.5 atmospheres for 90 minutes, 5 days per week for 30 treatments
Study: 30239456
Drug: Exponential tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exponential tapering (n = 79)
Study: 30239456
Drug: Linear tapering
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linear tapering (n = 79)
Study: 28905498
Drug: Bimagrumab 30
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 30 mg/kg i.v.
Study: 28166861
Drug: Dignity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity therapy (DT) + standard palliative care (SPC)
Study: 19837300
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of recombinant human erythropoietin (rHuEPO) at 150 IU/kg, 4 doses at 48-hour intervals
Study: 19837300
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 0.5 mL/kg isotonic solution
Study: 12638100
Drug: Heatwrap therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heatwrap therapy
Study: 9607135
Drug: Intravenous procainamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous procainamide (1 g over 30 minutes, followed by an infusion of 2 mg/min over 1 hour)
Study: 2243887
Drug: Oral pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pilocarpine (25 mg)
Study: 354047
Drug: Oxamniquine (Vansil)
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine (Vansil) at an oral dose of 15 mg/kg twice a day for 2 days (total dose 60 mg/kg)
Study: 31347100
Drug: IDegLira (fixed-ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegLira (fixed-ratio combination of insulin degludec and liraglutide)
Study: 28150516
Drug: Alternative insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternative insulin regimens
Study: 16402278
Drug: Paclitaxel alone
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel alone (175 mg/m2/IV)
Study: 16402278
Drug: Paclitaxel with
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel with Tamoxifen (TAM) (160 mg/m2 PO BID on Days 1-5 followed by paclitaxel 175 mg/m2/IV on Day 5)
Study: 15306531
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg (n = 12)
Study: 8353089
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg three times a day for 15 days
Study: 29923950
Drug: Costoclavicular approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Costoclavicular approach (Gp-CC)
Study: 27543595
Drug: Standardized daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standardized daptomycin dosing protocol
Study: 25231685
Drug: Comprehensive pharmacologic
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive pharmacologic cancer pain therapy (CPT)
Study: 28436380
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) monotherapy
Study: 20600025
Drug: Fixed-dose emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed-dose emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) combination therapy
Study: 23939953
Drug: TDF monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF monotherapy
Study: 20600025
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (FTC/TDF)
Study: 8874257
Drug: diuretic responsive
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: diuretic responsive (group A; n = 6)
Study: 8874257
Drug: diuretic resistant
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: diuretic resistant (group B; n = 23)
Study: 15310639
Drug: Caudal 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1)
Study: 15310639
Drug: Caudal 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 2 microg.kg(‐1)
Study: 15310639
Drug: Caudal 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 3 microg.kg(‐1)
Study: 15310639
Drug: Caudal 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 4 microg.kg(‐1)
Study: 7747094
Drug: Roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 150 mg bid for 10 days
Study: 2687356
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg haloperidol i.v.
Study: 1098396
Drug: methyldopa, 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyldopa, 750 mg/day
Study: 1098396
Drug: spironolactone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: spironolactone, 200 mg/day
Study: 1098396
Drug: combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined treatment with spironolactone and methyldopa
Study: 1098396
Drug: spironolactone, 100
Normalized name: Spironolactone, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: spironolactone, 100 mg/day
Study: 30717797
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg intravenously every 2 weeks (1 L‐mn subgroup)
Study: 30717797
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg intravenously every 2 weeks (2 L subgroup)
Study: 28911141
Drug: Intramuscular glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular glucagon administration
Study: 28911141
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro glucagon treatment
Study: 26285330
Drug: Balneo- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneo- and peloid therapy using sulfide-containing siltypeloids
Study: 23638898
Drug: Dosage-continued group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage-continued group (n=14)
Study: 17999271
Drug: Individual cognitive-behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive-behaviour therapy (ICBT)
Study: 17999271
Drug: Group cognitive-behaviour
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behaviour therapy (GCBT)
Study: 6990861
Drug: Cimetidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.0 g daily)
Study: 2923963
Drug: Ranitidine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (1.2 g daily)
Study: 22781020
Drug: G‐WWB (white
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐WWB (white wheat bread enriched with guar gum)
Study: 20656965
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation therapy
Study: 17336254
Drug: General therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: General therapies for MDS
Study: 10334256
Drug: Intranasal 17
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17 beta-oestradiol (S21400) 100 microg, 200 microg, 300 microg, or 400 microg
Study: 10334256
Drug: Oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol valerate 1 mg or 2 mg
Study: 10334256
Drug: Intranasal 17
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17 beta-oestradiol (S21400)
Study: 28045958
Drug: rhEGF (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEGF (50 microg/mL)
Study: 20868384
Drug: Basic fibroblast
Normalized name: Basic Fibroblast Growth Factor
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic fibroblast growth factor (bFGF) spray daily
Study: 7772359
Drug: lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 1.5 mg/kg
Study: 17358099
Drug: dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextrose 5% 5 mL (control)
Study: 15848532
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (stopped steroids)
Study: 15848532
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (continued steroids)
Study: 11981384
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (60 mW, transmeatal, once a week for 6 minutes, 4 times over 4 weeks)
Study: 11981384
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser treatment (transmeatal, once a week for 6 minutes, 4 times over 4 weeks)